Back
Open Access

A placebo-correcetd effect of the initial eGFR decline following SGLT-2 inhibitor initiation: a systematic review and meta-analysis

Session: Vericiguat, SGLT2 inhibitors and implementation
Topic: Pharmacotherapy
Speaker: Doctor S. Urban (Lubin, PL)
Event: Heart Failure 2025

Congress Presentation

Add to my library

Like

About the speaker

Doctor Szymon Urban

Copper Health Centre, Lubin (Poland)
0 follower

6 more presentations in this session

Scarred for life - outcomes of ischaemic and non-ischaemic cardiomyopathy after heart failure optimisation

Speaker: Doctor O. Graham (Craigavon, GB)

Access
Abstract
Like
Thumbnail

Estimated multinational budget impact of empagliflozin for heart failure patients with full spectrum of left ventriclular ejection fraction

Speaker: Doctor E. Kim (Seoul, KR)

Access
Abstract
Like
Thumbnail

Vericiguat in a real-world heart failure population: a single-centre experience

Speaker: Mr C. Palacios-Castello (Seville, ES)

Access
Abstract
Like
Thumbnail

Quantifying the burden of potentially inappropriate prescribed medicines among people hospitalised with heart failure in Australia: a comparison with ESC recommendations

Speaker: Associate Professor M. Falster (Sydney, AU)

Access
Abstract
Like
Thumbnail

The effect of dapagliflozin on the microvascular endothelial cell function and metabolism in patients with heart failure: a preliminary report

Speaker: Doctor M. Tarnawska (Gdansk, PL)

Access
Abstract
Like
Thumbnail

Access the full session

Vericiguat, SGLT2 inhibitors and implementation

Speakers: Doctor S. Urban, Doctor O. Graham, Doctor E. Kim, Mr C. Palacios-Castello, Associate Professor M. Falster...
Access
Like
Thumbnail

About the event

Image

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novartis Explore sponsored resources
logo Novo Nordisk Explore sponsored resources